JPS6227079B2 - - Google Patents

Info

Publication number
JPS6227079B2
JPS6227079B2 JP54078317A JP7831779A JPS6227079B2 JP S6227079 B2 JPS6227079 B2 JP S6227079B2 JP 54078317 A JP54078317 A JP 54078317A JP 7831779 A JP7831779 A JP 7831779A JP S6227079 B2 JPS6227079 B2 JP S6227079B2
Authority
JP
Japan
Prior art keywords
acetylmuramyl
alanyl
compound
group
isoglutaminyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54078317A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5618996A (en
Inventor
Tetsuo Shiba
Shozo Kotani
Juichi Yamamura
Osamu Nagase
Hidemasa Ogawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP7831779A priority Critical patent/JPS5618996A/ja
Priority to AU59101/80A priority patent/AU534233B2/en
Priority to ZA00803483A priority patent/ZA803483B/xx
Priority to CA000354017A priority patent/CA1183128A/en
Priority to PH24162A priority patent/PH15892A/en
Priority to AT80103461T priority patent/ATE2958T1/de
Priority to SU802936451A priority patent/SU1190990A3/ru
Priority to ES492664A priority patent/ES8200645A1/es
Priority to DE8080103461T priority patent/DE3062609D1/de
Priority to EP80103461A priority patent/EP0021367B1/en
Priority to US06/162,233 priority patent/US4317771A/en
Publication of JPS5618996A publication Critical patent/JPS5618996A/ja
Publication of JPS6227079B2 publication Critical patent/JPS6227079B2/ja
Priority to LTRP302A priority patent/LT2135B/xx
Priority to LV930118A priority patent/LV5277A3/xx
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP7831779A 1979-06-21 1979-06-21 Muramyldipeptide derivative Granted JPS5618996A (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP7831779A JPS5618996A (en) 1979-06-21 1979-06-21 Muramyldipeptide derivative
AU59101/80A AU534233B2 (en) 1979-06-21 1980-06-06 Muramyldipeptide derivatives
ZA00803483A ZA803483B (en) 1979-06-21 1980-06-11 Muramyldipeptide derivatives
CA000354017A CA1183128A (en) 1979-06-21 1980-06-13 Muramyldipeptide derivatives
PH24162A PH15892A (en) 1979-06-21 1980-06-18 Muramyldipeptide derivatives
ES492664A ES8200645A1 (es) 1979-06-21 1980-06-20 Un procedimiento para la preparacion de un muramildipeptido.
SU802936451A SU1190990A3 (ru) 1979-06-21 1980-06-20 Способ получени производных мурамилдипептида
AT80103461T ATE2958T1 (de) 1979-06-21 1980-06-20 Muramyldipeptid-derivate, verfahren zur herstellung dieser verbindungen und diese enthaltende pharmazeutische zusammensetzungen.
DE8080103461T DE3062609D1 (en) 1979-06-21 1980-06-20 Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds
EP80103461A EP0021367B1 (en) 1979-06-21 1980-06-20 Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds
US06/162,233 US4317771A (en) 1979-06-21 1980-06-23 Muramyldipeptide derivatives
LTRP302A LT2135B (lt) 1979-06-21 1993-01-27 Muramildipeptido dariniu gavimo budas
LV930118A LV5277A3 (lv) 1979-06-21 1993-02-12 Muramildipeptida atvasinajumu iegusanas panemiens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7831779A JPS5618996A (en) 1979-06-21 1979-06-21 Muramyldipeptide derivative

Publications (2)

Publication Number Publication Date
JPS5618996A JPS5618996A (en) 1981-02-23
JPS6227079B2 true JPS6227079B2 (enExample) 1987-06-12

Family

ID=13658554

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7831779A Granted JPS5618996A (en) 1979-06-21 1979-06-21 Muramyldipeptide derivative

Country Status (11)

Country Link
US (1) US4317771A (enExample)
EP (1) EP0021367B1 (enExample)
JP (1) JPS5618996A (enExample)
AT (1) ATE2958T1 (enExample)
AU (1) AU534233B2 (enExample)
CA (1) CA1183128A (enExample)
DE (1) DE3062609D1 (enExample)
ES (1) ES8200645A1 (enExample)
PH (1) PH15892A (enExample)
SU (1) SU1190990A3 (enExample)
ZA (1) ZA803483B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482959A2 (fr) * 1979-06-29 1981-11-27 Rhone Poulenc Ind Nouveaux tripeptides, leur preparation et les medicaments qui les contiennent
GR78246B (enExample) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5920297A (ja) * 1982-07-27 1984-02-01 Dai Ichi Seiyaku Co Ltd ムラミルジペプチド誘導体
JPS59172497A (ja) * 1983-03-22 1984-09-29 Dai Ichi Seiyaku Co Ltd 新規ムラミルペプチド誘導体
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
US4474693A (en) * 1983-10-31 1984-10-02 E. R. Squibb & Sons, Inc. ACE inhibitors produced from Nocardia orientalis
JPS6157597A (ja) * 1984-08-29 1986-03-24 Toshiyuki Hamaoka ムラミルペプチド活性エステル誘導体
JPS6393724A (ja) * 1986-10-09 1988-04-25 Dai Ichi Seiyaku Co Ltd ムラミルジペプチド誘導体含有鎮痛消炎剤
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
CN100522995C (zh) * 2003-10-22 2009-08-05 中国医学科学院药物研究所 胞壁酰-丙氨酰-d-异谷氨酰胺衍生物、制法和其药物组合物与用途
US8907061B2 (en) 2008-01-11 2014-12-09 Lawrence Livermore National Security, Llc. Nanolipoprotein particles and related methods and systems for protein capture, solubilization, and/or purification
US9303273B2 (en) 2008-05-09 2016-04-05 Lawrence Livermore National Security, Llc Nanolipoprotein particles comprising a natural rubber biosynthetic enzyme complex and related products, methods and systems
WO2009143280A2 (en) * 2008-05-22 2009-11-26 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions, methods and systems
US10151037B2 (en) 2009-01-12 2018-12-11 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide dependent target reduction, and related methods and systems
CN103204901B (zh) 2010-05-27 2016-03-09 中国医学科学院药物研究所 紫杉醇共缀物的制备方法
CN102219834A (zh) * 2011-04-14 2011-10-19 北京市丰硕维康技术开发有限责任公司 一种制备罗莫肽的方法
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
WO2016138286A1 (en) 2015-02-26 2016-09-01 Stc.Unm Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH613709A5 (en) * 1975-12-10 1979-10-15 Ciba Geigy Ag Process for the preparation of glucosamine derivatives
FR2358159A1 (fr) * 1976-07-16 1978-02-10 Anvar Le diamide de l'acide 2-(2-acetamido-2-deoxy-3 - o-d-glucopyranosyl) - d-propionyl-l-alanyl-d-glutamique et medicaments le contenant
FI66878C (fi) * 1978-02-24 1984-12-10 Ciba Geigy Ag Foerfarande foer framstaellning av nya antigenderivat
FR2442241A2 (fr) * 1978-03-20 1980-06-20 Anvar Nouveaux composes esters de muramyl-peptide, leur preparation et les compositions pharmaceutiques les contenant, notamment sous forme de liposomes
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
US4256735A (en) * 1979-01-29 1981-03-17 Merck & Co., Inc. Immunologically active dipeptidyl saccharides and methods of preparation

Also Published As

Publication number Publication date
DE3062609D1 (en) 1983-05-11
EP0021367A1 (en) 1981-01-07
AU534233B2 (en) 1984-01-12
AU5910180A (en) 1981-01-08
SU1190990A3 (ru) 1985-11-07
US4317771A (en) 1982-03-02
PH15892A (en) 1983-04-14
ATE2958T1 (de) 1983-04-15
JPS5618996A (en) 1981-02-23
ZA803483B (en) 1981-06-24
CA1183128A (en) 1985-02-26
ES492664A0 (es) 1981-11-16
ES8200645A1 (es) 1981-11-16
EP0021367B1 (en) 1983-04-06

Similar Documents

Publication Publication Date Title
JPS6227079B2 (enExample)
DE3786250T2 (de) Phosphinsäure-Derivate.
HU190486B (en) Process for producing spiro /4./3+n// -2-azaalkane-3-carboxylic acid-derivatives and pharmaceutical compositions containing the same
FR2501199A1 (fr) Nouveaux polypeptides, leur preparation et leur application comme medicaments
KR960014104B1 (ko) 테이코플라닌 화합물의 치환 알킬아미드
US5688771A (en) Lipophilic oligopeptides with immunomodulating activity
DE2730549A1 (de) Peptidderivate und deren herstellung
HU209939B (en) Process for producing 34-de(acetyl-glycosaminyl)-34-deoxy-teicoplanin- -c63-amide derivatives
JP4307723B2 (ja) Ｎ１−修飾グリコペプチド
JPH0134999B2 (enExample)
US4487764A (en) New peptides and a process for their preparation
KR100209971B1 (ko) 항생제 a 40926 에스테르 유도체
JPH0414120B2 (enExample)
CA1247084A (en) Peptide process for preparation thereof and use thereof
KR840000010B1 (ko) 무라밀디펩타이드 유도체의 제조방법
DE2730524A1 (de) Peptidderivate und deren herstellung
US4666887A (en) Intravenous or intraperitoneal administration of a tripeptide compound for treating cancer
US6034055A (en) Glycosyl-amides of 2-aminoacylamino-2-deoxy-sugars
EP0053388B1 (en) New peptide, process for preparation thereof and use thereof
JPS59148745A (ja) 新規アシルグルタミルリジン誘導体
US3749706A (en) Novel dipeptide amide and process for its manufacture
JPH029898A (ja) シアル酸結合オクタペプチドおよびその製造方法
US4497729A (en) Peptide, process for preparation thereof and use thereof
US4476050A (en) Peptide, process for preparation thereof and use thereof
JPS6312879B2 (enExample)